Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.

Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, Hatton CS.

Int J Cancer. 2007 Sep 1;121(5):1156-61.

2.

[Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].

Cao QW, Li HY, Yao XX, Wang JF.

Zhonghua Xue Ye Xue Za Zhi. 2012 Dec;33(12):1010-4. Chinese.

PMID:
23363792
3.

Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.

Chen W, Wang H, Chen H, Liu S, Lu H, Kong D, Huang X, Kong Q, Lu Z.

Eur J Haematol. 2014;92(5):407-12. doi: 10.1111/ejh.12263. Epub 2014 Mar 10.

PMID:
24400911
4.

MicroRNA profiling of primary cutaneous large B-cell lymphomas.

Koens L, Qin Y, Leung WY, Corver WE, Jansen PM, Willemze R, Vermeer MH, Tensen CP.

PLoS One. 2013 Dec 16;8(12):e82471. doi: 10.1371/journal.pone.0082471. eCollection 2013.

5.

A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.

Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T.

Int J Oncol. 2010 Aug;37(2):367-76.

PMID:
20596664
6.

Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma.

Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS.

J Cell Mol Med. 2009 Jul;13(7):1248-60. doi: 10.1111/j.1582-4934.2008.00628.x. Epub 2008 Dec 24.

7.

[Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].

Yao XX, Wang JF, Wang YH, Gao N.

Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):366-70. doi: 10.3760/cma.j.issn.0529-5807.2012.06.002. Chinese.

PMID:
22932402
8.

Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, Guo S, Smith LM, Wright G, Bhagavathi S, Dybkaer K, Fu K, Greiner TC, Vose JM, Jaffe E, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Armitage JO, Weisenburger DD, Staudt LM, Gascoyne RD, McKeithan TW, Chan WC.

Blood. 2015 Feb 12;125(7):1137-45. doi: 10.1182/blood-2014-04-566778. Epub 2014 Dec 10.

9.

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.

10.

Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.

Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, Alizadeh AA, Lossos IS.

Blood. 2005 Apr 1;105(7):2924-32. Epub 2004 Dec 9.

11.
12.

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.

Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, Dave S, Xiao L, Cao K, Zhu Q, Sherman S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Müller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan TM, Staudt LM, Chan WC.

Am J Pathol. 2004 Jul;165(1):159-66.

13.

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.

14.
15.

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A; Lymphoma/Leukemia Molecular Profiling Project.

Blood. 2005 Nov 1;106(9):3183-90. Epub 2005 Jul 26.

16.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC.

Blood. 2004 Jan 1;103(1):275-82. Epub 2003 Sep 22.

17.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

18.

[Significance of miR-155, miR-34a and miR-30a expression in diffuse large B-cell lymphoma].

Sun GX, Cao XS, Li Q, Wang Z, Peng J, Lu CQ.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Feb;30(1):79-83. doi: 10.3760/cma.j.issn.1003-9406.2013.01.019. Chinese.

PMID:
23450486
19.

BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.

Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A.

J Pathol. 2005 Oct;207(2):243-9.

PMID:
16041695
20.

Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.

He M, Gao L, Zhang S, Tao L, Wang J, Yang J, Zhu M.

Gastric Cancer. 2014;17(3):431-41. doi: 10.1007/s10120-013-0313-3. Epub 2013 Nov 14.

PMID:
24232982
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk